orantinib has been researched along with raltitrexed in 2 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (raltitrexed) | Trials (raltitrexed) | Recent Studies (post-2010) (raltitrexed) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 580 | 143 | 121 |
| Protein | Taxonomy | orantinib (IC50) | raltitrexed (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 7.0667 | |
| Dihydrofolate reductase | Homo sapiens (human) | 1.8578 | |
| Thymidylate synthase | Lacticaseibacillus casei | 8.2667 | |
| Thymidylate synthase | Homo sapiens (human) | 1.208 | |
| Thymidylate synthase | Mus musculus (house mouse) | 0.67 | |
| Thymidylate synthase | Escherichia coli K-12 | 2.32 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 2.32 | |
| Folate receptor beta | Homo sapiens (human) | 0.384 | |
| Folate receptor alpha | Homo sapiens (human) | 0.015 | |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.26 | |
| Reduced folate transporter | Homo sapiens (human) | 0.0063 | |
| Thymidylate synthase | Rattus norvegicus (Norway rat) | 0.9 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 1.7956 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.0995 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Kisliuk, RL; Thorpe, JE; Zhao, Y | 1 |
2 other study(ies) available for orantinib and raltitrexed
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Indenes; Melanoma, Experimental; Mice; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2012 |